Strand Therapeutics is developing the first platform for creating programmable, long-acting mRNA therapeutics capable of delivering precise, multi-functional, potentially curative treatments. Welcome to the future of biology, today.
The first autonomous medicines
The real deal in synthetic bio
Strand was co-founded by world-leading mRNA researchers from the MIT Synthetic Biology Center.
Programmable pipeline
Strand has developed the first programming language for mRNA. Strand embeds mRNA therapeutics with sophisticated logic to enable them to identify which cell types they are in and then follow a programmed course of action.
Our team is developing a pipeline of programmable, long-acting mRNA therapeutics that are bioengineered to enable precise control of the location, timing, intensity, and duration of protein expression. With the company’s self-replicating mRNAs, Strand’s goal is to develop improved treatment options for cancer and other life-threatening diseases.
Partnerships
Our mission is to transform the lives of patients through the development of highly targeted, potentially curative programmable mRNA therapeutics. We are open to exploring opportunities to expand our programs.
Join our team
Strand is building a team that understands the value of working at an emerging biotech. Joining the company now means having vast opportunities to learn and grow, including exposure to all aspects of building a company.
